1 Title

4

8

10

11

22

24

- 2 No association between circulating levels of testosterone and sex
- 3 hormone-binding globulin and risk of COVID-19 mortality in UK biobank

5 Authors

- 6 Xikang Fan¹*, Jing Yang¹*, Jiayu Wang¹, Cheng Yin², Meng Zhu¹, Hongxia
- 7 Ma^{1,3,4}, Guangfu Jin^{1,3,4}, Zhibin Hu^{1,3,4}, Hongbing Shen^{1,4}, Dong Hang^{1,4}
- ^{*} Co-first authors, contributed equally.

Affiliations

- ¹ Department of Epidemiology and Biostatistics, International Joint Research
- 13 Center on Environment and Human Health, Center for Global Health, School
- of Public Health, Nanjing Medical University, Nanjing, China, 211166;
- ² Department of Laboratory, Jiangning Hospital Affiliated to Nanjing Medical
- University, Nanjing, China, 211100;
- ³ State Key Laboratory of Reproductive Medicine, Center for Global Health,
- Nanjing Medical University, Nanjing, China, 211166;
- ⁴ Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment,
- 20 Collaborative Innovation Center for Cancer Medicine, Nanjing Medical
- University, Nanjing, China, 211166.
- 23 **Short title:** sex hormone and COVID-19 mortality

25 Correspondence:

- 26 Dong Hang, PhD
- 27 Department of Epidemiology and Biostatistics, School of Public Health,
- Nanjing Medical University, 101 Longmian Avenue, Nanjing 211166, China.
- 29 Email: hangdong@njmu.edu.cn

Funding

30

31

38

40

- This study was funded by National Natural Science Foundation of China
- 33 (81820108028, 81521004, and 81973127), National Key R&D Program of
- 34 China (2016YFC1000200 and 2017YFC0908300), and Science Foundation for
- Excellent Young Scholars of Jiangsu (BK20190083). The funders had no role
- in study design, data collection and analysis, decision to publish, or
- 37 preparation of the manuscript.
- 39 **Disclosure Summary:** The authors have nothing to disclose.

41 Abbreviations

- 42 COVID-19: coronavirus disease 2019; SHBG: sex hormone-binding globulin;
- 43 FT: free testosterone; TT: total testosterone; SARS-CoV-2: severe acute
- respiratory syndrome coronavirus 2; NHS: National Health Service; BMI: body
- mass index; MET, metabolic equivalent; ICD: international classification of
- 46 diseases; HRT: hormone replacement treatment; OR: odds ratio; CI:

47 confidence interval; SD: standard deviation.

Abstract

48

- 49 **Background:** Sex-disaggregated data suggest that men with coronavirus
- disease 2019 (COVID-19) are more likely to die than women. Whether
- 51 circulating testosterone or sex hormone-binding globulin (SHBG) contributes
- to such sex differences remains unknown.
- Objective: To evaluate the associations of circulating total testosterone (TT),
- free testosterone (FT), and SHBG with COVID-19 mortality.
- 55 **Design:** Prospective analysis.
- 56 **Setting:** UK Biobank.
- 57 Participants: We included 1306 COVID-19 patients (678 men and 628
- 58 women) who had serum TT and SHBG measurements and were free of
- cardiovascular disease or cancer at baseline (2006-2010).
- 60 Main outcome measures: The death cases of COVID-19 were identified from
- 61 National Health Service death records updated at 31 July 2020. Unconditional
- logistic regression was performed to estimate the odds ratio (OR) and 95%
- confidence intervals (CI) for mortality.
- Results: We documented 315 deaths of COVID-19 (194 men and 121
- women). After adjusting for potential confounders, we did not find any
- statistically significant associations for TT (OR per 1-SD increase = 1.03, 95%
- 67 CI: 0.85-1.25), FT (OR per 1-SD increase = 0.95, 95% CI: 0.77-1.17), or SHBG
- 68 (OR per 1-SD increase = 1.09, 95% CI: 0.87-1.37) with COVID-19 mortality in
- men. Similar null results were observed in women (TT: OR per 1-SD increase

- 70 = 1.10, 95% CI: 0.85-1.42; FT: OR per 1-SD increase = 1.10, 95% CI:
- 0.82-1.46; SHBG: OR per 1-SD increase = 1.16, 95% CI: 0.89-1.53).
- 72 **Conclusions:** Our findings do not support a significant role of circulating
- testosterone or SHBG in COVID-19 prognosis.

74

75 **Keywords:** testosterone, sex hormone, COVID-19, mortality, UK Biobank

Introduction

76

97

The coronavirus disease 2019 (COVID-19) pandemic is a global health 77 78 emergency that has led to more than 870,000 deaths worldwide 79 (https://covid19.who.int/). According to sex-disaggregated data from many affected countries, there seem to be sex differences in severity and mortality of 80 the disease (1-3). Men with COVID-19 are more likely to need intensive care 81 82 and to die than women, with an overall case-fatality ratio of approximately 1.7 83 (4). Several hypotheses have been proposed to account for the difference, 84 such as smoking, co-morbid conditions, immune responses, and sex 85 hormones (4, 5). As the most abundant circulating androgen in men, 86 testosterone has been suggested as an immunosuppressive factor by 87 inhibiting B lymphopoiesis, T-helper 1 differentiation, and inflammatory 88 cytokine production (6, 7). However, epidemiologic data are sparse regarding 89 the association between circulating testosterone levels and COVID-19 prognosis in either men or women. 90 Most circulating testosterone is tightly bound to sex hormone-binding 91 92 globulin (SHBG) or weakly bound to albumin, and a minor amount exists as 93 free testosterone (FT) (8). In the current study, we leveraged the UK Biobank resource, with recently released data on COVID-19 tests and updated death 94 95 records, to examine the associations of total testosterone (TT), calculated FT, and SHBG with mortality among COVID-19 patients. 96

Methods

Study design and participants

UK Biobank enrolled over 500,000 community-dwelling individuals (aged 37-73 years) across the UK during 2006 to 2010 (9). At the baseline assessment, participants completed self-administered touchscreen questionnaires, had physical measurements by qualified nurses, and provided blood samples.

According to the Public Health England database linked to UK biobank updated at 3 August 2020, a total of 9773 participants had undergone severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tests, among whom 1638 were diagnosed with COVID-19. We also included 161 participants who died from COVID-19 according to the National Health Service (NHS) death records. Exclusion criteria included COVID-19 patients who had no available data on serum TT (n=286) or SHBG (n=309), who had a self-reported history of cardiovascular disease (n=176) or cancer (n=138) at blood draw, and who died from other causes (n=22). Finally, 1306 patients with COVID-19 were included in the analysis, consisting of 678 men and 628 women.

Assessment of biomarkers

Serum concentrations of TT and SHBG were measured by chemiluminescent immunoassays (Beckman Coulter DXI 800), with analytical ranges of 0.35-55.52 nmol/L and 0.33-242 nmol/L, respectively. A colorimetric method

was used to assay albumin (Beckman Coulter AU5800), with an analytical range of 15-60 g/L. Overall, the average coefficients of variation for TT, SHBG, and albumin ranged from 3.66-8.34%, 5.22-5.67%, and 2.09-2.20%, respectively. Moreover, each assay was registered with an external quality assurance scheme to verify the accuracy, showing that more than 95% of participated distributions for these biomarkers were good or acceptable. FT was calculated using a validated algorithm based on TT, SHBG, albumin, and the association constants for the binding of testosterone to SHBG and albumin (10, 11)

Ascertainment of COVID-19 Mortality

Date and cause of death were obtained through linkage to national death registries. Primary cause of mortality was defined using the 10th revision of the International Statistical Classification of Diseases, and the outcome of our analysis was mortality due to COVID-19 (U07). Available death data we used were last updated at 31 July 2020.

Ascertainment of Covariates

Information on age, sex, education, ethnicity, smoking status, and alcohol consumption was self-reported in the baseline questionnaires. Townsend deprivation index was evaluated by incorporating measures of unemployment, household overcrowding, and non-ownership of home or car. Body mass index

(BMI) was calculated as weight in kilograms divided by height in meters squared derived from physical measurements. Total physical activity was assessed by total metabolic equivalent task minutes per week for all activity, including walking, moderate, and vigorous activity.

Statistical Analysis

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

Testosterone and SHBG concentrations were log-transformed to improve normality. Because the date of SARS-CoV-2 testing did not represent the date of getting infected, the survival time from infection to death or the last follow-up could not be accurately calculated for each patient, rendering Cox regression models inapplicable in the current analysis. We used unconditional logistic regression models to estimate odds ratios (OR) and 95% confidence intervals (CI), according to quintiles and continuously per 1-standard deviation (SD) increment in hormone concentrations. The model was first adjusted for major covariates including age at infection, sex, and ethnicity (simple model), then further adjusted for Townsend deprivation index, BMI, smoking status, alcohol drinking, physical activity, and for women, menopause status and hormone replacement treatment (HRT) (full model). Stratified analyses were conducted according to the median age at infection (<70, ≥70 years), sex (male, female), BMI (<30, ≥30 kg/m²), physical activity (≤median, >median), and smoking status (never, ever) in the full

models. To estimate potential effect modification by these stratification

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

variables, we used a likelihood ratio test comparing the models with and without interaction terms between hormone levels and each stratification variable. In addition, sensitivity analysis was performed by excluding participants with self-rated poor overall health at baseline. All analyses were performed with SAS 9.4. Statistical tests were all two-sided, and P < 0.05 was regarded as statistically significant. Results Among 678 male and 628 female patients with COVID-19, 194 (28.6%) and 121 (19.3%) deaths occurred, respectively. The median time from blood draw to COVID-19 testing was 11.1 years (interquartile range: 10.5-11.9 years). TT concentrations ranged from 1.96-27.45 nmol/L in men and 0.35-4.44 nmol/L in women (Figure \$1). SHBG concentrations ranged from 2.59-133.66 nmol/L in men and 10.15-218.89 nmol/L in women. **Table 1** summarizes the main characteristics of COVID-19 patients by quartiles of TT levels. FT and SHBG levels increased with TT levels. Moreover, patients with higher TT tended to be younger at blood draw. Men with higher BMI and women using HRT were more likely to have lower TT levels. **Tables 2 and 3** showed the association results for the hormones and COVID-19 mortality in men and women, respectively. We did not find any statistically significant associations for TT (fully adjusted OR per 1-SD increase = 1.03, 95% CI: 0.85-1.25), FT (fully adjusted OR per 1-SD increase = 0.95, 95% 186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

CI: 0.77-1.17), or SHBG (fully adjusted OR per 1-SD increase = 1.09, 95% CI: 0.87-1.37) with COVID-19 mortality in men. Similar null results were observed in women (TT: fully adjusted OR per 1-SD increase = 1.10, 95% CI: 0.85-1.42; FT: fully adjusted OR per 1-SD increase = 1.10, 95% CI: 0.82-1.46; SHBG: fully adjusted OR per 1-SD increase = 1.16, 95% CI: 0.89-1.53). The forest plot of stratified analyses (Figure 1) showed that none of the stratification variables had modification effects on TT, FT, and SHBG levels in men and women. The sensitivity analysis also indicated that the hormones were not associated with COVID-19 mortality (**Tables S1 and S2**). **Discussion** To the best of our knowledge, this is the first study to assess the association of pre-diagnostic testosterone and SHBG levels with COVID-19 mortality. We did not observe any statistically significant associations in either men (n=678) or women (n=628), suggesting that circulating testosterone and SHBG may not play a critical role in COVID-19 prognosis. In support of our findings, a prior study of 543 male patients with COVID-19 from UK Biobank did not identify any significant associations for baseline TT and SHBG levels with an increased risk of SARS-CoV-2 infection or hospitalization (12). However, in another study of 31 male patients with COVID-19 in Italy, lower TT and FT levels were associated with a higher risk of

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

clinical deterioration (intensive care unit transfer or death) (13). Meanwhile, another study of 221 male patients reported that those who died from COVID-19 had lower mean TT levels than the patients alive (14). These two smaller studies were limited by inadequate adjustment for confounders, and they measured testosterone when patients were already hospitalized with COVID-19, which could introduce reverse causation. The proposed leading cause of COVID-19 deterioration is the intense inflammatory response, known as a cytokine storm, which severely damages the lung tissue and causes acute respiratory distress syndrome (15). Sex differences in the response to inflammation have been well documented and can be attributed to various factors including sex hormones (16, 17). The current study suggests that circulating testosterone and SHBG may not be implicated in COVID-19 prognosis. However, we were unable to evaluate the association between estrogens and COVID-19 mortality because the majority of estradiol measurements were below the limit of detection in UK biobank. In a published cross-sectional study, serum estradiol showed negative correlations with severity of COVID-19 and levels of cytokines related to inflammation (18). Animal experiments also showed that estrogen signaling could suppress the inflammatory reactions and decrease severe acute respiratory syndrome coronavirus titers, leading to improved survival, while androgens did not influence disease outcome in male mice (19). Therefore, further studies are warranted to clarify whether and how estrogens have a

beneficial effect on COVID-19 prognosis.

The major strengths of our study include the prospective design, reliable data on hormone levels and COVID-19, detailed data on covariates that allowed for robust confounding control, and evaluation of the associations both in men and women separately. However, two major limitations should be acknowledged. First, baseline hormones were assessed only one time, which may not reflect a long-time exposure. However, the intraclass correlation coefficients of TT and SHBG between two measurements (4 years apart in UK biobank) were 0.59 (95% CI: 0.58-0.61) and 0.86 (95% CI: 0.86-0.87), respectively, in men; 0.63 (95% CI: 0.62-0.64) and 0.81 (95% CI: 0.80-0.82), respectively, in women, indicating that a single measurement can reliably categorize average levels over at least a 4-year period (20). Second, limited by the coverage of COVID-19 testing, ascertainment bias may have occurred in the current study.

Conclusions

Our findings indicate that circulating levels of testosterone and SHBG are not associated with COVID-19 prognosis. Future studies may focus on other factors to unreal the mechanisms underlying sex differences in COVID-19 mortality.

Acknowledgments

We are grateful to UK Biobank participants. This research has been conducted

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

using the UK Biobank resource under application number 52217. **Author Contributions** DH was responsible for the conception and design of the study. XF and DH had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis. XF and JY did the statistical analysis and drafted the manuscript. JW, CY, MZ, HM, GJ, ZH, and HS critically revised the manuscript for important intellectual content. All authors reviewed and approved the final manuscript. References 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. 2. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. Jama. 2020. 3. Klein SL, Dhakal S, Ursin RL, Deshpande S, Sandberg K, Mauvais-Jarvis F. Biological sex impacts COVID-19 outcomes. PLoS Pathog. 2020;16(6):e1008570. 4. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat

- 274 Rev Immunol. 2020;20(7):442-7.
- 5. Chakravarty D, Nair SS, Hammouda N, Ratnani P, Gharib Y, Wagaskar V,
- et al. Sex differences in SARS-CoV-2 infection rates and the potential link to
- 277 prostate cancer. Commun Biol. 2020;3(1):374.
- 6. Trigunaite A, Dimo J, Jørgensen TN. Suppressive effects of androgens on
- the immune system. Cell Immunol. 2015;294(2):87-94.
- 7. Gubbels Bupp MR, Jorgensen TN. Androgen-Induced
- Immunosuppression. Front Immunol. 2018;9:794.
- 8. Raverot V, Lopez J, Grenot C, Pugeat M, Déchaud H. New approach for
- measurement of non-SHBG-bound testosterone in human plasma. Anal Chim
- 284 Acta. 2010;658(1):87-90.
- 9. Collins R. What makes UK Biobank special? Lancet.
- 286 2012;379(9822):1173-4.
- 10. Rinaldi S, Geay A, Dechaud H, Biessy C, Zeleniuch-Jacquotte A,
- Akhmedkhanov A, et al. Validity of free testosterone and free estradiol
- determinations in serum samples from postmenopausal women by theoretical
- calculations. Cancer Epidemiol Biomarkers Prev. 2002;11(10 Pt 1):1065-71.
- 11. Södergård R, Bäckström T, Shanbhag V, Carstensen H. Calculation of free
- and bound fractions of testosterone and estradiol-17 beta to human plasma
- proteins at body temperature. J Steroid Biochem. 1982;16(6):801-10.
- 12. Ghazizadeh Z, Majd H, Richter M, Samuel R, Zekavat SM, Asgharian H, et
- 295 al. Androgen Regulates SARS-CoV-2 Receptor Levels and Is Associated with

- Severe COVID-19 Symptoms in Men. bioRxiv. 2020.
- 13. Rastrelli G, Di Stasi V, Inglese F, Beccaria M, Garuti M, Di Costanzo D, et
- 298 al. Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2
- 299 pneumonia patients. Andrology. 2020.
- 14. Çayan S, Uğuz M, Saylam B, Akbay E. Effect of serum total testosterone
- and its relationship with other laboratory parameters on the prognosis of
- coronavirus disease 2019 (COVID-19) in SARS-CoV-2 infected male patients:
- a cohort study. Aging Male. 2020:1-11.
- 15. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et
- al. COVID-19: consider cytokine storm syndromes and immunosuppression.
- 306 Lancet. 2020;395(10229):1033-4.
- 16. Al-Lami RA, Urban RJ, Volpi E, Algburi AMA, Baillargeon J. Sex Hormones
- and Novel Corona Virus Infectious Disease (COVID-19). Mayo Clin Proc.
- 309 2020;95(8):1710-4.
- 17. Giefing-Kroll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B. How
- sex and age affect immune responses, susceptibility to infections, and
- response to vaccination. Aging Cell. 2015;14(3):309-21.
- 18. Ding T, Zhang J, Wang T, Cui P, Chen Z, Jiang J, et al. Potential Influence
- of Menstrual Status and Sex Hormones on female SARS-CoV-2 Infection: A
- 315 Cross-sectional Study from Multicentre in Wuhan, China. Clin Infect Dis. 2020.
- 19. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK,
- Perlman S. Sex-Based Differences in Susceptibility to Severe Acute

Respiratory Syndrome Coronavirus Infection. J Immunol.

2017;198(10):4046-53.

20. Dashti SG, Viallon V, Simpson JA, Karahalios A, Moreno-Betancur M,

English DR, et al. Explaining the link between adiposity and colorectal cancer

risk in men and postmenopausal women in the UK Biobank: A sequential

causal mediation analysis. Int J Cancer. 2020;147(7):1881-94.

324

Table 1. Baseline characteristics of COVID-19 patients according to quartiles of serum TT levels in men and women

		Serum TT	levels in men, nm	Serum TT levels in women, nmol/L				
Characteristic	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Characteristic	(1.96-9.32)	(9.32-11.25)	(11.25-13.65)	(13.67-27.45)	(0.35-0.75)	(0.75-1.01)	(1.01-1.40)	(1.40-4.44)
Participants N	169	169	170	169	135	135	135	135
Age at blood draw, mean (SD), y	58.76 (8.75)	56.22 (9.14)	57.62 (8.97)	56.53 (8.99)	56.21 (9.07)	54.51 (8.84)	52.71 (9.48)	53.38 (9.65)
Age at infection, mean (SD),	69.91 (8.82)	67.43 (9.23)	68.80 (9.00)	67.65 (8.99)	67.32 (9.07)	65.61 (8.98)	63.91 (9.49)	64.70 (9.66)
White race, No. (%)	144 (85.21)	144 (85.21)	148 (87.06)	148 (87.57)	120 (88.89)	115 (85.19)	120 (88.89)	118 (87.41)
Body mass index, mean (SD), kg/m ²	30.82 (4.66)	28.68 (4.23)	28.18 (4.54)	26.79 (3.81)	29.03 (6.60)	28.15 (5.41)	27.81 (5.50)	29.19 (5.93)
Physical activity, mean (SD), MET-hours/w	46.20 (53.77)	48.93 (50.76)	47.22 (46.24)	42.82 (38.66)	42.19 (38.11)	41.68 (43.33)	42.76 (39.92)	38.48 (36.35)
Townsend deprivation index, mean (SD)	-0.11 (3.65)	-0.13 (3.39)	-0.51 (3.32)	0.03 (3.64)	-0.23 (3.55)	-0.77 (3.23)	-0.48 (3.32)	-0.65 (3.14)
Smoking status, No. (%) ^a								
Never	52 (30.77)	76 (44.97)	89 (52.35)	71 (42.01)	83 (61.48)	67 (49.63)	83 (61.48)	81 (60.00)
Previous	88 (52.07)	73 (43.20)	63 (37.06)	76 (44.97)	37 (27.41)	42 (31.11)	37 (27.41)	40 (29.63)
Current	24 (14.20)	19 (11.24)	17 (10.00)	21 (12.43)	14 (10.37)	25 (18.52)	15 (11.11)	13 (9.63)
Alcohol consumption, No. (%) ^a								
Daily to three times a week	73 (43.20)	62 (36.69)	76 (44.71)	79 (46.75)	32 (23.70)	31 (22.96)	38 (28.15)	38 (28.15)
Twice a week to once a month	61 (36.09)	67 (39.64)	62 (36.47)	60 (35.50)	58 (42.96)	54 (40.00)	57 (42.22)	58 (42.96)
Never or special	32 (18.93)	39 (23.08)	32 (18.82)	30 (17.75)	44 (32.59)	50 (37.04)	39 (28.89)	39 (28.89)

Had menopause, No. (%)	NA	NA	NA	NA	70 (51.85)	66 (48.89)	60 (44.44)	60 (44.44)
Ever used HRT, No. (%)	NA	NA	NA	NA	54 (40.00)	43 (31.85)	32 (23.70)	29 (21.48)
SHBG, nmol/L	27.62 (11.13)	33.30 (12.18)	39.34 (11.43)	53.17 (22.18)	57.07 (29.76)	61.39 (31.20)	63.11 (28.18)	58.97 (30.56)
FT, nmol/L	0.13 (0.03)	0.16 (0.04)	0.17 (0.04)	0.19 (0.07)	0.006 (0.002)	0.008 (0.003)	0.011 (0.004)	0.018 (0.009)

Abbreviations: TT, total testosterone; MET, metabolic equivalent; HRT, hormone-replacement therapy; NA, not appliable; SHBG, sex hormone-binding globulin; FT, free testosterone.

^a The total did not sum to 100% because small proportions of participants chose "prefer not to answer" on some questions.

Table 2. Associations of serum TT, FT, and SHBG levels with COVID-19 mortality in men

	Q1	Q2	Q3	Q4	P-trend	OR per 1-SD increment ^c
		Quartile of serum				
Cutpoints, nmol/L	1.96-9.32	9.32-11.25	11.25-13.65	13.67-27.45	_	
No. of cases	49	48	58	39		
Simple model ^a	ref	1.31 (0.78-2.21)	1.54 (0.93-2.55)	0.93 (0.54-1.58)	0.99	1.00 (0.83-1.20)
Full model ^b	ref	1.39 (0.81-2.38)	1.71 (1.00-2.93)	1.02 (0.58-1.81)	0.73	1.03 (0.85-1.25)
		Quartile of FT	levels, OR (95% CI)			
Cutpoints, nmol/L	0.04-0.13	0.13-0.15	0.15-0.19	0.19-0.58	_	
No. of cases	61	48	40	29		
Simple model ^a	ref	0.98 (0.59-1.62)	0.94 (0.55-1.60)	0.98 (0.54-1.79)	0.67	0.96 (0.78-1.17)
Full model ^b	ref	0.97 (0.58-1.63)	0.92 (0.53-1.58)	0.97 (0.53-1.78)	0.64	0.95 (0.77-1.17)
Cutpoints, nmol/L	2.59-25.99	26.16-35.32	35.34-46.57	46.65-133.66	_	
No. of cases	31	46	44	58		
Simple model ^a	ref	1.23 (0.68-2.20)	0.83 (0.46-1.49)	1.11 (0.62-1.98)	0.64	1.05 (0.85-1.30)
Full model ^b	ref	1.33 (0.73-2.44)	0.89 (0.48-1.63)	1.20 (0.65-2.22)	0.44	1.09 (0.87-1.37)

Abbreviations: TT, total testosterone; FT, free testosterone; SHBG, sex hormone-binding globulin; OR, odds ratio; CI, confidence interval; ref, reference.

^a Adjusted for age at infection, sex, and race.

^b Additionally adjusted for Townsend deprivation index, body mass index, smoking status, alcohol drinking, and physical activity.

^c SD was the standard deviation of log-transformed hormone levels: 0.31 for TT, 0.31 for FT, and 0.46 for SHBG.

Table 3. Associations of serum TT, FT, and SHBG levels with COVID-19 mortality in women

	Q1	Q2	Q3	Q4	P-trend	OR per 1-SD increment ^c
Cutpoints, nmol/L	0.35-0.75	0.75-1.01	0.75-1.01 1.01-1.40 1.40-4.4			
No. of cases	26	26	16	28		
Simple model ^a	ref	1.25 (0.64-2.46)	0.75 (0.35-1.57)	1.49 (0.76-2.93)	0.41	1.11 (0.87-1.42)
Full model ^b	ref	1.17 (0.57-2.39)	0.71 (0.32-1.57)	1.38 (0.68-2.81)	0.46	1.10 (0.85-1.42)
		Quartile of FT	levels, OR (95% CI)			
Cutpoints, nmol/L	0.002-0.006	0.006-0.009	0.006-0.009			
No. of cases	23	17	20	26		
Simple model ^a	ref	0.75 (0.36-1.59)	0.87 (0.42-1.81)	1.37 (0.67-2.80)	0.11	1.24 (0.95-1.60)
Full model ^b	ref	0.79 (0.36-1.74)	0.75 (0.35-1.63)	1.05 (0.48-2.31)	0.53	1.10 (0.82-1.46)
		Quartile of SHB	G levels, OR (95% CI)			
Cutpoints, nmol/L	10.15-37.58	37.63-54.35	54.42-76.08	76.98-218.89		
No. of cases	28	28	29	26		
Simple model ^a	ref	1.19 (0.62-2.27)	1.42 (0.74-2.71)	0.91 (0.47-1.77)	0.86	0.98 (0.78-1.24)
Full model ^b	ref	1.48 (0.75-2.93)	1.99 (0.97-4.09)	1.46 (0.68-3.14)	0.28	1.16 (0.89-1.53)

Abbreviations: TT, total testosterone; FT, free testosterone; SHBG, sex hormone-binding globulin; OR, odds ratio; CI, confidence interval; ref, reference.

^a Adjusted for age at infection, sex, and race.

^b Additionally adjusted for Townsend deprivation index, body mass index, smoking status, alcohol drinking, physical activity, menopause status, and hormone replacement treatment.

^c SD was the standard deviation of log-transformed hormone levels: 0.46 for TT, 0.59 for FT, and 0.51 for SHBG.

Figure Legend

325

326

- Figure 1. Forest plots of stratified analysis for the associations of serum total
- testosterone, free testosterone, and sex hormone-binding globulin levels with
- 328 COVID-19 mortality.

	Male					Femal	e			
Subgroup	Total N	N case	s	OR per 1-SD	<i>P</i> −interaction	Total N	N case	es	OR per 1-SD	<i>P</i> -interaction
тт				increment (95% CI)					increment (95% CI)	
Age at infection (years)					0.33					0.92
<70	322	34		1.72 (1.07-2.76)		339	22	-	1.31 (0.81-2.12)	
≥70	355	160	+	0.92 (0.74-1.14)		201	74	-	1.11 (0.80-1.53)	
BMI (kg/m²)					0.57					0.89
<30	466	125	+	0.95 (0.75-1.21)		369	54		1.30 (0.87-1.93)	
≥30	211	69		1.31 (0.92-1.86)		171	42	-	1.13 (0.76-1.69)	
Physical activity (MET-hour/week)					0.16					0.99
Below	385	116	-	1.21 (0.93-1.58)		347	69	-	1.08 (0.79-1.47)	
Above	292	78	+	0.88 (0.65-1.18)		193	27	-	1.07 (0.61-1.87)	
Smoking status					0.73					0.55
Never	288	66	-	1.13 (0.79-1.62)		314	51	-	0.99 (0.69-1.43)	
Ever	381	126	+	1.07 (0.84-1.36)		223	45	-	1.18 (0.79-1.77)	
FT										
Age at infection (years)					0.77					0.85
<70	289	29		1.22 (0.73-2.04)		304	22		1.20 (0.71-2.02)	
≥70	330	149	+	0.88 (0.69-1.11)		182	64		1.20 (0.82-1.74)	
BMI (kg/m²)					0.04					0.49
<30	432	120	-	0.80 (0.62-1.05)		332	48		1.35 (0.85-2.13)	
≥30	187	58	-	1.31 (0.90-1.91)		154	38	-	1.12 (0.70-1.78)	
Physical activity (MET-hour/week)					0.44					0.94
Below	352	105	-	1.13 (0.86-1.48)		313	63	-	1.06 (0.76-1.49)	
Above	267	73	-	0.75 (0.53-1.06)		173	23	-	1.08 (0.56-2.10)	
Smoking status					0.41					0.94
Never	262	60	-	1.21 (0.83-1.76)		286	47	-	1.01 (0.69-1.50)	
Ever	349	116	-	0.86 (0.66-1.12)		197	39	-	1.14 (0.71-1.82)	
SHBG										
Age at infection (years)					0.44					0.73
<70	290	29	-	1.41 (0.89-2.22)		351	27	-	1.29 (0.77-2.16)	
≥70	331	150	+	1.02 (0.78-1.32)		223	84	-	1.06 (0.75-1.50)	
BMI (kg/m²)					0.17					0.61
<30	433	121	-	1.19 (0.89-1.59)		396	68	_	1.14 (0.79-1.66)	
≥30	188	58	+	1.01 (0.69-1.50)		178	43		1.20 (0.73-1.99)	
Physical activity (MET-hour/week)					0.44					0.60
Below	354	106	-	1.16 (0.86-1.55)		369	80	-	1.10 (0.79-1.51)	
Above	267	73	+	1.03 (0.71-1.48)		205	31	-	1.34 (0.73-2.48)	
Smoking status					0.76					0.20
Never	264	61	+	0.94 (0.63-1.39)		340	58	+	1.09 (0.76-1.57)	
Ever	349	116	-	1.24 (0.93-1.65)		229	53		1.36 (0.87-2.10)	
			0.5 1 1.5 2 2.5 3					0.5 1 1.5 2 2.5		